已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

阿霉素 医学 软组织肉瘤 临床终点 蒽环类 肉瘤 肿瘤科 内科学 临床研究阶段 化疗 外科 临床试验 癌症 病理 乳腺癌
作者
William D. Tap,Robin L. Jones,Brian A. Van Tine,Bartosz Chmielowski,Anthony Elias,Douglas Adkins,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory Pennock,Meera Hameed,Gaurav Shah,Amy Qin,Ashwin Shahir,Damien M. Cronier,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz
出处
期刊:The Lancet [Elsevier]
卷期号:388 (10043): 488-497 被引量:507
标识
DOI:10.1016/s0140-6736(16)30587-6
摘要

Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any, novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody that has antitumour activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue sarcoma.We did an open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA. For both the phase 1b and phase 2 parts of the study, eligible patients were aged 18 years or older and had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue sarcoma not previously treated with an anthracycline, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and available tumour tissue to determine PDGFRα expression by immunohistochemistry. In the phase 2 part of the study, patients were randomly assigned in a 1:1 ratio to receive either olaratumab (15 mg/kg) intravenously on day 1 and day 8 plus doxorubicin (75 mg/m(2)) or doxorubicin alone (75 mg/m(2)) on day 1 of each 21-day cycle for up to eight cycles. Randomisation was dynamic and used the minimisation randomisation technique. The phase 1b primary endpoint was safety and the phase 2 primary endpoint was progression-free survival using a two-sided α level of 0.2 and statistical power of 0.8. This study was registered with ClinicalTrials.gov, number NCT01185964.15 patients were enrolled and treated with olaratumab plus doxorubicin in the phase 1b study, and 133 patients were randomised (66 to olaratumab plus doxorubicin; 67 to doxorubicin alone) in the phase 2 trial, 129 (97%) of whom received at least one dose of study treatment (64 received olaratumab plus doxorubicin, 65 received doxorubicin). Median progression-free survival in phase 2 was 6.6 months (95% CI 4.1-8.3) with olaratumab plus doxorubicin and 4.1 months (2.8-5.4) with doxorubicin (stratified hazard ratio [HR] 0.67; 0.44-1.02, p=0.0615). Median overall survival was 26.5 months (20.9-31.7) with olaratumab plus doxorubicin and 14.7 months (9.2-17.1) with doxorubicin (stratified HR 0.46, 0.30-0.71, p=0.0003). The objective response rate was 18.2% (9.8-29.6) with olaratumab plus doxorubicin and 11.9% (5.3-22.2) with doxorubicin (p=0.3421). Steady state olaratumab serum concentrations were reached during cycle 3 with mean maximum and trough concentrations ranging from 419 μg/mL (geometric coefficient of variation in percentage [CV%] 26.2) to 487 μg/mL (CV% 33.0) and from 123 μg/mL (CV% 31.2) to 156 μg/mL (CV% 38.0), respectively. Adverse events that were more frequent with olaratumab plus doxorubicin versus doxorubicin alone included neutropenia (37 [58%] vs 23 [35%]), mucositis (34 [53%] vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%] vs 15 [23%]). Febrile neutropenia of grade 3 or higher was similar in both groups (olaratumab plus doxorubicin: eight [13%] of 64 patients vs doxorubicin: nine [14%] of 65 patients).This study of olaratumab with doxorubicin in patients with advanced soft-tissue sarcoma met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement of 11.8 months in median overall survival, suggesting a potential shift in the treatment of soft-tissue sarcoma.Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
于冷松完成签到,获得积分10
1秒前
科研通AI2S应助金全全采纳,获得10
3秒前
西域卧虎完成签到 ,获得积分10
3秒前
ChouNic完成签到 ,获得积分10
4秒前
tuanheqi完成签到,获得积分0
4秒前
Sylvia_J完成签到 ,获得积分10
5秒前
5秒前
辛勤钧发布了新的文献求助10
5秒前
Lshyong完成签到 ,获得积分10
5秒前
圆滚滚完成签到,获得积分10
6秒前
WWW完成签到 ,获得积分10
6秒前
彭于晏应助accept采纳,获得10
6秒前
7秒前
完美世界应助askfhasihfa采纳,获得10
7秒前
pgg完成签到,获得积分10
8秒前
喝可乐的萝卜兔完成签到 ,获得积分10
9秒前
阿东c完成签到 ,获得积分10
9秒前
圆滚滚发布了新的文献求助10
10秒前
隔壁小黄完成签到 ,获得积分10
10秒前
wang完成签到,获得积分10
11秒前
景行行止完成签到 ,获得积分10
11秒前
符fu完成签到 ,获得积分10
11秒前
血茗完成签到 ,获得积分10
13秒前
Chasing完成签到 ,获得积分10
15秒前
17秒前
e麓绝尘完成签到 ,获得积分10
19秒前
852应助谦让寄容采纳,获得10
19秒前
20秒前
galaxy发布了新的文献求助10
21秒前
皮皮完成签到 ,获得积分10
23秒前
爆米花应助babe采纳,获得10
25秒前
李健应助babe采纳,获得10
25秒前
25秒前
25秒前
27秒前
谨慎达完成签到 ,获得积分10
27秒前
谦让寄容发布了新的文献求助10
29秒前
Bizibili完成签到,获得积分10
30秒前
31秒前
Akim应助闪光喵喵采纳,获得10
31秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234449
求助须知:如何正确求助?哪些是违规求助? 2880760
关于积分的说明 8216976
捐赠科研通 2548347
什么是DOI,文献DOI怎么找? 1377713
科研通“疑难数据库(出版商)”最低求助积分说明 647944
邀请新用户注册赠送积分活动 623304